Novel Dermatology Drug Delivery Systems Preclinical stage

Medicine fails on time, not chemistry.

Moradyne builds novel dermatology drug delivery systems: depots that hold a proven therapeutic exactly where it acts and release it over days, not minutes. We are rebuilding topical treatment around duration and target site, in a field whose dosing paradigm has not meaningfully changed in decades.

The approach Investor relations

Scroll

Right molecule · wrong duration Proven actives · failing delivery Applied everywhere · delivered nowhere Reapply · forget · relapse Decades · one dosing paradigm Right molecule · wrong duration Proven actives · failing delivery Applied everywhere · delivered nowhere Reapply · forget · relapse Decades · one dosing paradigm

Moradyne Therapeutics is a preclinical-stage biopharmaceutical company dedicated to correcting market inefficiencies in drug development by closing the gap between scientific literature and available therapies.

What if trichogenic drug development has missed that this is the most potent hair growth stimulant in existence?

The active metabolite responsible for the effect — formed in the follicle itself, and almost never delivered there in a form that lasts.

The status quo

The drugs work.
The regimen doesn't.

For a class of widely-used topical therapies, efficacy was never really the problem. Delivery is. The dose is spread across a surface it was never meant to treat, and holding any benefit demands daily, indefinite reapplication. The field has accepted that trade-off for a generation.

Adherence

<50%

of patients on daily topical regimens remain adherent past the first year.

Reapplication

730×/yr

twice-daily dosing means a patient must not forget roughly seven hundred times a year, indefinitely.

Targeting

Applied everywhere.
Delivered nowhere.

A topical dose lands on the whole treatment field, not the structure that needs it. Most of it spreads across the surface, absorbs systemically or is simply washed away. Only a small fraction ever reaches the follicle, where the biology actually happens. Efficacy is limited by where the drug ends up, not by whether it works.

Innovation gap

~30yrs

since the last real step-change in how these actives reach their target. The molecule modernised, the vehicle did not.

Consequence

Relapse

stopping resets the clock. Benefit stays contingent on a routine most people cannot sustain for life.

The approach

A delivery company, first.

We start from actives that already work and re-engineer where they go and how long they stay. A delivery architecture, rather than a new chemical entity, is the faster and lower-risk path to a therapy people can actually keep taking.

Target

Deposit, don't spread

The therapeutic is placed into the follicular reservoir at the target and held there, instead of washing across a surface and clearing.

Duration

Meter over days

The depot releases its payload on a sustained schedule, turning a spike-and-crash curve into a steady plateau above the threshold that matters.

Regimen

From daily to occasional

If one application lasts days, the adherence problem changes shape entirely. Compliance stops depending on memory.

Scope

A platform, not a product

The same architecture generalises. Prove it once and it points at a family of indications that share the same failure mode.

Founder

Built by one operator,
advised by specialists.

Moradyne is run as a focused, capital-efficient venture: a single founder driving the programme, with senior academic formulation scientists on the science.

Lucas J. Rosenthal Founder & Managing Director

MedicineLMU Munich — current medical student

Prior degreesUSC · HKUST · Bocconi

Operating modelLean, preclinical, decision-gated

AdvisorsSenior academic formulation SAB

The science of what to deliver is largely solved. The problem worth a company is where it goes and how long it stays.

Moradyne was founded on a deceptively simple conviction: that some of medicine's most stubborn treatment failures are not failures of discovery, but of delivery. Rather than chase new molecules, the company re-engineers the vehicle around proven actives — a leaner, sharper path to a therapy people can actually stay on.

Lucas is a current medical student at LMU Munich and holds three bachelor degrees from USC, HKUST and Bocconi. Clinical training alongside a business and pharmacology background across three continents is what the company is built around: reading the primary literature closely enough to find the gap, and structuring the venture tightly enough to close it.

Working method

Dig into otherwise obscure literature. Examine the gaps it leaves open, and the findings the field abandoned before the tools existed to test them properly. Evaluate what is worth re-examining. Then pursue the preclinical work that shows whether a gap can be exploited in translational drug development. Most of the value in this field is sitting in papers nobody went back to.

Moradyne advances its lead programme alongside senior academic formulation scientists, toward the data that determines value.

Clinical

Trained to read the source

Medical training at LMU Munich, used to work through primary literature rather than reviews of it.

Commercial

Structured for diligence

Business and finance grounding from USC, HKUST and Bocconi, applied to how the venture is staged and financed.

Scientific

Run with specialists

Formulation and preclinical work carried out with senior academic scientists rather than in-house headcount.

Pipeline

One architecture.
A widening set of targets.

Our lead program is advancing through preclinical development. Follow-on candidates apply the same delivery system to adjacent indications that share the same underlying problem.

MDX-852Lead candidate

Sustained-release dermatology depot for an indication with a large, treatment-resistant population underserved by daily regimens.

Preclinical testing commencing soon

Preclinical · formulation locked

MDX-922Follow-on

Platform extension into a second indication sharing the same delivery mechanism and manufacturing route.

Discovery · formulation

PlatformUndisclosed

Additional targets under evaluation. Details reserved pending intellectual-property review.

Research · evaluation

Investor relations

A focused asset,
built for diligence.

Platform, not a single shotA delivery architecture designed to generalise across multiple indications.
De-risked by designBuilt on proven actives: reformulation risk, not discovery risk.
Capital-efficient pathA lean model around senior academic partnerships and staged, decision-gated spend.
Clear inflection pointsPreclinical data packages structured from day one to withstand strategic-acquirer review.

Confidential materials

Start a conversation.

We share detailed materials with qualified investors and strategic partners under confidentiality. Reach out and we will take it from there.

Request materials